Home › Cases › Tumour Lysis Syndrome
Tumour Lysis Syndrome
Tumour Lysis Syndrome
6 questions
Question 1 · Recognition and Cairo-Bishop Criteria
Correct answer: Tumour Lysis Syndrome (TLS) — meets both laboratory and clinical Cairo-Bishop criteria
Why
Tumour Lysis Syndrome (TLS) occurs when massive tumour cell lysis releases intracellular contents into the bloodstream. Cairo-Bishop criteria define laboratory TLS as ≥2 different metabolic abnormalities: hyperuricaemia (uric acid ≥476 μmol/L), hyperkalaemia (K+ ≥6.0 mmol/L), hyperphosphataemia (PO₄ ≥1.45 mmol/L), hypocalcaemia (Ca²⁺ ≤1.75 mmol/L); the same parameters can instead qualify by a ≥25% rise in urate/potassium/phosphate or ≥25% fall in calcium. Count ≥2 different parameters, all within 3 days before or 7 days after chemotherapy. Clinical TLS requires laboratory TLS plus ≥1 of: creatinine ≥1.5× upper normal, cardiac arrhythmia, seizure. Mr Chen meets all four metabolic criteria plus renal impairment — this is clinical TLS requiring emergency management.
Key point
Cairo-Bishop criteria for TLS: ≥2 of hyperuricaemia, hyperkalaemia, hyperphosphataemia, hypocalcaemia ± renal impairment, arrhythmia, or seizure = clinical TLS.
Question 2 · Risk Stratification
Correct answer: Haematological malignancies with high tumour burden and rapid cell turnover — particularly Burkitt's lymphoma, ALL, and AML with high WCC
Why
High-risk TLS is driven by high tumour burden, rapid cell turnover and chemosensitivity. Burkitt/lymphoblastic lymphoma is high risk when advanced, or early with LDH ≥2× ULN or bulk; early non-bulky disease with LDH <2× ULN is intermediate. AML with WCC ≥100×10⁹/L and ALL with WCC ≥100×10⁹/L and/or bulk are high risk. In DLBCL/other high-grade lymphoma, stage, LDH and bulk determine low/intermediate/high risk; bulk alone is not universally high risk in early-stage disease. Spontaneous TLS can occur before treatment. CLL receiving venetoclax has low–high risk, depending on tumour burden and patient factors, including renal function. Solid tumours rarely cause TLS except for bulky, chemosensitive tumours such as small cell lung cancer or germ cell tumours. Pre-existing renal impairment, dehydration, and baseline hyperuricaemia increase risk regardless of tumour type.
Key point
High tumour burden and chemosensitivity drive TLS risk. Stage, LDH and bulk matter in Burkitt's/lymphoma; WCC ≥100×10⁹/L identifies high-risk AML/ALL, with bulky ALL also high risk. Assess renal function and treatment-specific risk.
Question 3 · Prevention
Correct answer: IV 0.9% NaCl hydration + prophylactic rasburicase (e.g. 3 mg IV once), after G6PD check, with haematology-led monitoring/repeat dosing
Why
For this high-risk Burkitt's lymphoma patient, start prophylaxis before chemotherapy: IV hydration with 0.9% NaCl, strict fluid balance and haematology-led rasburicase prophylaxis. A single 3 mg IV adult prophylactic dose may be sufficient; repeat dosing is guided by blood tests and the haematology protocol. Check G6PD status: rasburicase is contraindicated in known deficiency. Allopurinol 300 mg PO OD (xanthine oxidase inhibitor) reduces uric acid synthesis from purine breakdown: it is inexpensive and used for low/intermediate-risk prophylaxis, but does not reduce existing uric acid or provide an adequate high-risk plan on its own. Rasburicase (recombinant urate oxidase) is reserved for high-risk or established TLS; it is expensive and contraindicated in G6PD deficiency. Avoid routine bicarbonate alkalinisation because it can worsen calcium phosphate precipitation. Avoid nephrotoxic drugs and NSAIDs.
Key point
High-risk Burkitt's: IV hydration + haematology-led rasburicase prophylaxis before chemotherapy; check G6PD, monitor bloods/fluid balance. Allopurinol alone is not the high-risk plan.
Question 4 · Established TLS — Rasburicase
Correct answer: Start rasburicase 0.2 mg/kg IV — but first check for G6PD deficiency, as rasburicase is contraindicated
Why
Rasburicase (recombinant urate oxidase) rapidly converts uric acid to allantoin (water soluble, easily excreted), reducing uric acid levels within hours — far more effective than allopurinol for established TLS. Dose is 0.2 mg/kg IV daily for up to 5 days. Critical contraindication: G6PD deficiency — rasburicase generates hydrogen peroxide as a by-product, causing haemolytic anaemia and methaemoglobinaemia in G6PD-deficient patients. Blood samples for uric acid must be collected on ice (transported to lab on ice immediately) as rasburicase remains active ex vivo and will falsely lower levels. Febuxostat is a xanthine oxidase inhibitor but has no established role in acute TLS. Allopurinol cannot reduce existing uric acid — it only prevents new production. Very unwell with delayed G6PD result: responsible consultant decides urgent treatment after individual risk–benefit review; never give in known G6PD deficiency. Stop allopurinol when rasburicase starts; it may restart 24 h after the last dose.
Key point
Rasburicase rapidly lowers uric acid in established TLS. Check G6PD: known deficiency risks life-threatening haemolysis and contraindicates use. Very unwell with result delayed: responsible consultant decides urgent treatment after individual risk–benefit review.
Question 5 · Managing Hyperkalaemia in TLS
Correct answer: IV calcium gluconate 10% 30 mL over 10 minutes immediately to stabilise the myocardium, then insulin-dextrose to shift potassium intracellularly
Why
ECG changes (peaked T waves, widened QRS, sine wave pattern) indicate cardiac membrane instability from hyperkalaemia — this is life-threatening and requires immediate cardioprotection. The treatment sequence is: 1) Calcium gluconate 10% 30 mL IV over 10 minutes (stabilises cardiac membrane within 3 minutes — does not lower K+, just protects the heart); 2) Insulin 10 units IV + 50 mL of 50% glucose (shifts K+ intracellularly, lowers K+ by 0.5–1.5 mmol/L over 30–60 min); 3) Nebulised salbutamol 10–20 mg (additional intracellular shift); 4) Oral sodium zirconium cyclosilicate or patiromer as an adjunct (removes K+ from gut; does not replace rapid-acting treatment); 5) Haemodialysis if refractory. Calcium resonium is no longer recommended for routine acute use; a binder alone first is dangerous when ECG changes are present. Check BM before insulin, then at 30, 60, 90 and 120 minutes and hourly to 6 hours; extend monitoring after repeat doses/high risk. If pre-treatment BM <7 mmol/L, follow with 10% glucose 50 mL/hr for 5 hours.
Key point
ECG changes + hyperkalaemia = calcium gluconate IV first to protect the myocardium, then insulin-dextrose to shift K+ intracellularly.
Question 6 · Renal Replacement Therapy Indications
Correct answer: RRT indications in TLS: refractory hyperkalaemia, uraemic complications, oliguria/anuria unresponsive to fluids, severe hyperphosphataemia, or fluid overload
Why
Renal replacement therapy (RRT) — typically continuous veno-venous haemodiafiltration (CVVHDF) or haemodialysis — is indicated in TLS when metabolic derangements are refractory to medical management: refractory hyperkalaemia (e.g. K+ ≥6.5 despite treatment; do not wait for ECG changes), severe AKI (oliguria/anuria, rising creatinine/uraemia), severe hyperphosphataemia causing symptomatic hypocalcaemia, fluid overload, or metabolic acidosis (pH <7.1). In TLS specifically, haemodialysis is preferred over peritoneal dialysis as it more efficiently clears uric acid and phosphate. RRT is not contraindicated in haematological malignancy — thrombocytopenia requires careful anticoagulation management but is not an absolute contraindication. Early nephrology input is essential. Base RRT on the whole clinical condition, not a fixed creatinine cutoff. Ongoing cell lysis means the threshold for specialist RRT consideration may be lower.
Key point
RRT in TLS is indicated for refractory hyperkalaemia, oligo-anuria, severe hyperphosphataemia, or fluid overload — haemodialysis clears urate and phosphate more efficiently than PD.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.